Verastem Inc (NASDAQ:VSTM) — Market Cap & Net Worth
Market Cap & Net Worth: Verastem Inc (VSTM)
Verastem Inc (NASDAQ:VSTM) has a market capitalization of $491.00 Million ($491.00 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12626 globally and #2951 in its home market, demonstrating a -6.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verastem Inc's stock price $5.84 by its total outstanding shares 87835106 (87.84 Million). Analyse VSTM cash flow metrics to see how efficiently the company converts income to cash.
Verastem Inc Market Cap History: 2015 to 2026
Verastem Inc's market capitalization history from 2015 to 2026. Data shows change from $1.96 Billion to $512.96 Million (-12.75% CAGR).
Index Memberships
Verastem Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #323 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1205 of 3165 |
Weight: Verastem Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verastem Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verastem Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.93x
Verastem Inc's market cap is 21.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $3.54 Billion | $26.72 Million | -$72.43 Million | 132.55x | N/A |
| 2019 | $1.41 Billion | $17.46 Million | -$149.21 Million | 80.91x | N/A |
| 2020 | $2.25 Billion | $88.52 Million | -$67.73 Million | 25.36x | N/A |
| 2021 | $2.16 Billion | $2.05 Million | -$71.20 Million | 1052.48x | N/A |
| 2022 | $424.24 Million | $2.60 Million | -$73.81 Million | 163.42x | N/A |
| 2024 | $454.11 Million | $10.00 Million | -$130.64 Million | 45.41x | N/A |
| 2025 | $678.09 Million | $30.91 Million | -$209.47 Million | 21.93x | N/A |
Competitor Companies of VSTM by Market Capitalization
Companies near Verastem Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Verastem Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Verastem Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Verastem Inc's market cap moved from $1.96 Billion to $ 512.96 Million, with a yearly change of -12.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $512.96 Million | -24.35% |
| 2025 | $678.09 Million | +49.32% |
| 2024 | $454.11 Million | -36.49% |
| 2023 | $714.98 Million | +68.53% |
| 2022 | $424.24 Million | -80.37% |
| 2021 | $2.16 Billion | -3.76% |
| 2020 | $2.25 Billion | +58.96% |
| 2019 | $1.41 Billion | -60.12% |
| 2018 | $3.54 Billion | +9.45% |
| 2017 | $3.24 Billion | +174.11% |
| 2016 | $1.18 Billion | -39.78% |
| 2015 | $1.96 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Verastem Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $491.00 Million USD |
| MoneyControl | $491.00 Million USD |
| MarketWatch | $491.00 Million USD |
| marketcap.company | $491.00 Million USD |
| Reuters | $491.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more